Latest Pyrazoles Stories
The Oncology Institute of Hope and Innovation announces first clinical trial of the year. Downey, CA (PRWEB) January 10, 2015 The Oncology Institute
TAINAN, Nov. 10, 2014 /PRNewswire/ -- ScinoPharm Taiwan, Ltd (TWSE: 1789) and Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
- Ceritinib achieved overall response rate of 58.5%, with a median progression-free survival of 8.2 months1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis today announced data showing
- Zykadia (ceritinib) demonstrated an overall response rate of 54.6% in patients with ALK+ metastatic NSCLC who have no other treatment option EAST HANOVER, N.J., April 29, 2014 /PRNewswire/
DeepResearchReports.com offers "2014 Deep Research Report on Global and China FIPRONIL Industry" and "2014 Deep Research Report on Global and China Azoxystrobin Industry" market
- Data showed investigational treatment LDK378 (ceritinib) also achieved a median progression-free survival of seven months EAST HANOVER, N.J., March 26, 2014 /PRNewswire/ -- Novartis today
The findings of a recent study indicate that routine testing with both fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) may enhance the detection of ALK-positive non-small cell lung cancer (NSCLC).
PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene.